Skip to main content

UroGen Pharma Ltd.

URGN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001668243

In the last 90 days, UroGen Pharma Ltd. insiders filed 0 open-market purchases and 4 sales; 190 institutions reported holding it in 13F filings for Q2 2026, worth $1.56B in total; ARK Invest is the only superinvestor holding it.

Q2 2021 vs. Q1 2021

How the institutions holding UroGen Pharma Ltd. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of URGN: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders8982−7
Shares14.3M14.0M−306.4K (−2.1%)
Value$278.5M$213.7M−$64.8M (−23.3%)

New holders (7)

Institutions that held UroGen Pharma Ltd. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to URGN in Q2 2021
InstitutionSharesValue% of portfolio
Tudor Investment Corp Et Al25,048$382.0K0.01%
Susquehanna Fundamental Investments, LLC21,831$333.0K0.01%
Squarepoint Ops LLC21,554$329.0K0.00%
State Board of Administration of Florida Retirement System15,641$239.0K0.00%
Jacobs Levy Equity Management, Inc13,548$207.0K0.00%
Mirae Asset Global Investments Co., Ltd.363$6.00K0.00%
State of Wyoming66$1.00K0.00%

Sold out (14)

Institutions that held UroGen Pharma Ltd. at the end of Q1 2021 and filed for Q2 2021 without it.